@article{014409e001164e1baa22496f3c6ef4f7,
title = "An update on mesoporous silica nanoparticle applications in nanomedicine",
abstract = "The efficient and safe delivery of therapeutic drugs, proteins, and nucleic acids are essential for meaningful therapeutic benefits. The field of nanomedicine shows promising implications in the development of therapeutics by delivering diagnostic and therapeutic compounds. Nanomedicine development has led to significant advances in the design and engineering of nanocarrier systems with supra-molecular structures. Smart mesoporous silica nanoparticles (MSNs), with excellent biocompatibility, tunable physicochemical properties, and site-specific functionalization, offer efficient and high loading capacity as well as robust and targeted delivery of a variety of payloads in a controlled fashion. Such unique nanocarriers should have great potential for challenging biomedical applications, such as tissue engineering, bioimaging techniques, stem cell research, and cancer therapies. However, in vivo applications of these nanocarriers should be further validated before clinical translation. To this end, this review begins with a brief introduction of MSNs properties, targeted drug delivery, and controlled release with a particular emphasis on their most recent diagnostic and therapeutic applications.",
keywords = "Bioimaging, Cancer therapy, Mesoporous silica nanoparticles, Stem cell research, Tissue engineering",
author = "Elham Rastegari and Hsiao, {Yu Jer} and Lai, {Wei Yi} and Lai, {Yun Hsien} and Yang, {Tien Chun} and Chen, {Shih Jen} and Huang, {Pin I.} and Chiou, {Shih Hwa} and Mou, {Chung Yuan} and Yueh Chien",
note = "Funding Information: This study was funded by Technology (MOST) (MOST 108-2320-B-010-019-MY3; MOST 109-2327-B-010-007), Ministry of Health and Welfare (MOHW)(MOH W108-TDU-B-211-133001, MOHW 109-TDU-B-211-114001, MOHW 110-TDU-B-211-124001), VGH, NTUH Joint Research Program (VN109-16, VN110-12), VGH, TSGH, NDMC, AS Joint Research Program (VTA107-V1-5-1, VTA108-V1-5-3, VTA109-V1-4-1; VTA110-V1-2-1), AS Clinical Research Center (IBMS-CRC109-P04), National Yang Ming Chiao Tung University (NYCU), Nano Targeting and Therapy Biopharma. Inc., AnnJi Pharmaceutical Joint Research Program (109J038); the “Cancer Progression Research Center, National Yang-Ming University” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, and the Ministry of Education through the SPROUT Project-Center For Intelligent Drug Systems and Smart Bio-devices (IDS2B) of National Chiao Tung University and, Taiwan. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
month = jul,
doi = "10.3390/pharmaceutics13071067",
language = "English",
volume = "13",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",
}